Ferric Citrate in CKD Treatment Analysis

Conduct an analysis of the elements of the research article you identified. Be sure to include the following:

Your topic of interest.

A correctly formatted APA citation of the article you selected, along with link or search details.,

Identify a professional practice use of the theories/concepts presented in the article.,

Analysis of the article using the “Research Analysis Matrix” section of the template

Write a 1-paragraph justification stating whether you would recommend this article to inform professional practice.

Write a 2- to 3-paragraph summary that you will add to your Academic Success and Professional Development Plan that includes the following:

Describe your approach to identifying and analyzing peer-reviewed research.

Identify at least two strategies that you would use that you found to be effective in finding peer-reviewed researchIdentify at least one resource you intend to use in the future to find peer-reviewed researchLi and associates conducted research to determine whether ferric citrate is effective in treating anemia and hyperphosphatemia in individuals with chronic kidney disease (CKD). The Renal Failure Journal published the compilation and analysis of the meta-analysis’s findings under the heading “Ferric citrate for treating hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials”.

Anemia and hyperphosphatemia are common CKD consequences that are linked to a higher risk of cardiovascular events. Ferric citrate (FC), an iron-based phosphate binder, has been linked to improvements in anemia and hyperphosphatemia in earlier researchUp until February 21, 2022, a thorough search of the literature was done using databases such as PUBMED, EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials (CCRCT). The goal of the meta-analysis was to evaluate the safety, effectiveness, and financial benefits of treating CKD patients with hyperphosphatemia and anemia with ferric citrate.

The analysis includes 16 randomized clinical trials (RCTs) with a total of 1754 participants.  In addition, eight trials showed that ferric citrate was a more affordable treatment than placebo. The majority of adverse effects that occurred after receiving ferric citrate were moderate. APA